Q&A

Optimizing Clinical Supply For A Smoother Phase 2a To 2b Transition

Source: Catalent
gettyimages-637785818-170667a

In this Q&A, John Davis, Regional Manager of Clinical Supplies Management at Catalent, discusses how sponsors can successfully navigate clinical supply decisions for a multi-part Phase 2 study. Davis discusses Phase 2a, which is typically a proof-of-concept study centered around dosing, and Phase 2b, which is typically used to evaluate the safety and efficacy of the drug being trialed. 

VIEW THE Q&A!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Clinical Leader